Endpoints News reports that the drug recorded its second mid-stage miss of 2026. The outlet also reports that Contineum shares fell about 6% in premarket trading.
Contineum and J&J's PIPE-307 missed its Phase 2 depression trial goal, Endpoints News reports. The outlet describes the result as the drug's second mid-stage trial failure of 2026 and reports that Contineum shares fell about 6% premarket.
1.1K
1 post, first seen 1d ago
Endpoints News reports that the drug recorded its second mid-stage miss of 2026. The outlet also reports that Contineum shares fell about 6% in premarket trading.
Contineum and J&J's PIPE-307 missed its Phase 2 depression trial goal, Endpoints News reports. The outlet describes the result as the drug's second mid-stage trial failure of 2026 and reports that Contineum shares fell about 6% premarket.
Endpoints News@endptsContineum and J&J's depression drug failed a Phase 2 trial, its second mid-stage miss this year.
Not enough discussion yet.
No sentiment analysis available yet.
Endpoints News@endptsContineum and J&J's depression drug failed a Phase 2 trial, its second mid-stage miss this year.
Not enough discussion yet.
No sentiment analysis available yet.
—
Not ranked yet
—
Not ranked yet